Search

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

Stem cell therapy for Parkinson’s disease: researching for an 
effective cure

Neurodegenerative diseases are characterised by the chronic and progressive loss of neurons, which in turn results in loss of cognitive and physical functions. The World Health Organization has estimated that the disability-adjusted life years lost from neurological disease was about...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Addressing medical risk factors for diabetes and understanding the new systemic treatments

As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...

Nano-ophthalmology paves a new path in the future of eyecare

Introduction The treatments of ocular conditions in the field of ophthalmology varies from topical to surgical procedures. The field of nanotechnology is one of the fast-growing fields of medicine, which plays an important role in turning the impossibilities of the...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

The lived experience of benign essential blepharospasm

Benign essential blepharospasm (BEB) is a rare neurological condition which causes involuntary sustained or intermittent muscular contraction of both eyelids and upper facial muscles which cause closure of eyelids, abnormal facial expressions and distress [1]. The term dystonia is an...

Retinoblastoma, CureAll and the role of global clinical, capacity strengthening and research networks

Retinoblastoma (Rb), a rare childhood eye cancer, presents a particularly compelling example of how global health partnerships can operate at the intersection of different medical disciplines, in this case: ophthalmology, oncology and public health. This article places the work of...

Breakthroughs in the genetics of angle-closure glaucoma

Angle closure glaucoma (ACG) is not widely known to be a familial condition, yet the recent explosion of genetic data and large scale genome wide investigations have confirmed at least 13 genetic loci associated with ACG [1], and provided some...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....